Home › GLP-1 pill vs. injection for weight loss

Last reviewed Nov 15, 2026

GLP-1 pill vs. injection

We may earn a commission from some links on this page. How we make money.

Short answer: Both pill and injection forms of GLP-1 produce clinically meaningful weight loss. Pills offer needle-free daily dosing; injections are once-weekly. No head-to-head trial has compared pills to injections directly, so the numbers below come from separate studies.

The options at a glance

MedicationFormActive ingredientApproval
Wegovy pillDaily tabletSemaglutide 25 mgDec 2025 (FDA)
FoundayoDaily tabletOrforglipron 17.2 mgApr 2026 (FDA)
Wegovy injectionWeekly penSemaglutide 2.4 mgJun 2021 (FDA)
ZepboundWeekly pen or vialTirzepatide 15 mgNov 2023 (FDA)

Weight loss: what the trials show

These are results from separate trials in adults with obesity—not head-to-head comparisons:

  • Wegovy pill (semaglutide oral): 13.6% average body weight loss at 64 weeks in OASIS 4 (ITT population).
  • Wegovy injection (semaglutide subcutaneous): 14.9% at 68 weeks in STEP 1 (ITT), and up to 17.4% on-treatment.
  • Zepbound (tirzepatide): up to 20.9% at 72 weeks in SURMOUNT-1 (15 mg ITT).
  • Foundayo (orforglipron): 12.4% at 72 weeks in ATTAIN-1.

Because these trials enrolled different people at different time points, the numbers can't be compared directly. Zepbound's higher average reflects that tirzepatide acts on two hormones (GLP-1 and GIP) rather than one.

Side effects: pills vs. injections

Both forms cause GI side effects—nausea, vomiting, diarrhea—that tend to be worse during dose escalation and ease at steady state. Some differences between pills and injections:

  • GI event rate: About 74% of people on the Wegovy pill reported any GI event in OASIS 4, versus 44% nausea alone with the Wegovy injection in STEP 1 (different measures, different trials).
  • Belching: The Wegovy pill causes excessive belching (eructation) in about 14% of users—a side effect not commonly reported with injections.
  • Skin tingling: About 5% of Wegovy pill users report skin tingling or burning (dysesthesia), not seen with the injection form.
  • Injection-site reactions: About 6–9% of injection users report redness or discomfort at the injection site—not applicable to pills.

Needles: does it matter?

About 25% of adults report significant needle fear (trypanophobia) that could affect their willingness to use an injectable medication (PMC 2022 survey). For this group, a daily pill may remove a real barrier to starting treatment.

On the other hand, 91% of Wegovy injection users in clinical trials reported feeling comfortable with self-injection after training. Most people who try it find it manageable.

Daily routine: pill vs. injection

  • Wegovy pill: taken every morning on an empty stomach with up to 4 oz of water, then a 30-minute wait before eating or drinking. Requires a consistent morning routine.
  • Foundayo: taken once daily at any time, with or without food. No waiting period required.
  • Wegovy injection: once weekly, same day each week, by subcutaneous pen in stomach, thigh or upper arm. Refrigerated (or room-temp up to 28 days).
  • Zepbound: once weekly by subcutaneous pen (KwikPen) or vial. Refrigerated storage required; KwikPen can sit at room temp up to 21 days.

Cost comparison (self-pay, 2026)

MedicationCash price / monthMedicare Bridge covered?
Wegovy pill$149–$299Yes ($50/mo)
Foundayo$149–$299Yes ($50/mo)
Wegovy injection$349 ($199 for first 2 fills, new patients)Yes ($50/mo)
Zepbound KwikPen$349–$499 (LillyDirect)Yes ($50/mo for KwikPen)
Zepbound vials$299–$449 (LillyDirect)No (vials not covered)

On Medicare's GLP-1 Bridge, eligible Part D enrollees pay $50 per month for Wegovy pill, Foundayo, or Wegovy injection, or Zepbound KwikPen—but not Zepbound vials.

Which is right for you?

  • Choose a pill if: you have needle fear or aversion, want the simplest travel routine, or find a morning or anytime oral routine easier to stick to.
  • Choose an injection if: you prefer once-weekly dosing over daily, don't mind or prefer injections, or want the highest average weight-loss numbers from tirzepatide.
  • Ask your clinician: medical history, other medications, and insurance coverage all affect which form makes sense for you. Neither pills nor injections are for everyone.

To compare the two daily pills head to head, see Wegovy pill vs. Foundayo. For what to realistically expect on either form, see GLP-1 pill weight-loss results from clinical trials.

Ready to pick a form?

Ro and LifeMD list both the Wegovy pill and Foundayo; compare fees on our where-to-get page.

FAQ

Is the GLP-1 pill as effective as the injection?

In separate (not head-to-head) trials: the Wegovy pill produced 13.6% average weight loss at 64 weeks; the Wegovy injection 14.9% at 68 weeks; and Zepbound up to 20.9% at 72 weeks. These aren't directly comparable because trials enrolled different people at different times.

Which has more side effects, GLP-1 pills or injections?

Both cause GI side effects—nausea, diarrhea, vomiting—that are worst at dose escalation. Pills may add belching (14% with the Wegovy pill) and skin tingling (5%). Injections can cause injection-site reactions. Neither form is clearly 'worse' overall.

Can I switch from an injection to a pill?

Some people switch. A 2026 real-world study (OCTANE) found that people who switched from injectables to the Wegovy pill lost about 4% more weight on average over 3 months. Talk to your clinician about whether switching makes sense for you.

Does Medicare cover both pills and injections?

Yes—through the temporary Medicare GLP-1 Bridge, eligible Part D enrollees pay $50 per month for Wegovy pill, Foundayo, or the Wegovy injection, or Zepbound KwikPen (but not Zepbound vials). The Bridge runs through Dec 31, 2027.

Related guides

Sources